Celiac Disease Market to Witness Upsurge in Growth During the Study Period (2019-2032), Evaluates DelveInsight

The market size of Celiac Disease is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Takeda/Cour Pharmaceuticals, Precigen ActoBio, Falk Pharma, Zedira.

[Nevada, United States] - DelveInsight's "Celiac Disease Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Celiac Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Celiac Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Celiac Disease Market Report:
The Celiac Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In September, 2024: Sanofi (Provention Bio, a Sanofi Company) announced that a study will evaluate the efficacy and safety of PRV-015 in adult patients with non-responsive celiac disease (NRCD) who are on a gluten-free diet (GFD).
In August, 2024: Kanyos Bio, Inc. announced that the goal of their study is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
In MAY, 2024: Topas Therapeutics GmbH announced that the goal of their study is to learn about the safety and the pharmacodynamic (PD) effects of TPM502 in adults with celiac disease.
As per the Beyond Celiac foundation (2024), an estimated 1 in 133 Americans, or about 1% of the population, has celiac disease. It is also estimated that up to 83% of Americans who have celiac disease are undiagnosed or misdiagnosed with other conditions
According to the Stahl et al. (2023), Celiac disease is a common chronic condition, with a pooled global prevalence of 1.4% but can be much higher in certain regions. In a prospective birth cohort study of infants at risk for celiac disease in Europe and the United States, the estimated incidence was as high as 3% in Sweden and 2.4% in Colorado.
Key Celiac Disease Companies are as follows: 9 Meters Biopharma, ImmunogenX, Provention Bio, Takeda/Cour Pharmaceuticals, Precigen ActoBio, Falk Pharma, Zedira.
Key Celiac Disease Therapies are as follow: KAN-101, Larazotide Acetate (INN-202/AT-1001), Latiglutenase (IMGX003/ALV003), PRV-015, TAK-101, AG017, ZED1227.
Launching multiple stage Celiac Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Celiac Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Celiac Disease Overview:
Celiac disease is a chronic autoimmune disorder that affects the digestive system, primarily triggered by the consumption of gluten-a protein found in wheat, barley, and rye. When individuals with celiac disease ingest gluten, their immune system mistakenly attacks the lining of the small intestine, leading to damage and inflammation. This results in the impaired absorption of essential nutrients, causing a wide range of symptoms and potential complications if left untreated.

Celiac Disease Drugs Uptake and Pipeline Development Activities:
The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to be launched during the study period. The report covers market uptake by drugs, patient uptake by therapies, and sales of each drug. Additionally, it provides insights into Celiac Disease Pipeline Development Activities, analyzing therapeutic candidates in various stages and key companies involved.

For more information about Celiac Disease companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Celiac Disease Therapies and Key Companies:
Larazotide Acetate (INN-202/AT-1001): 9 Meters Biopharma
Latiglutenase (IMGX003/ALV003): ImmunogenX
PRV-015: Provention Bio
TAK-101: Takeda/Cour Pharmaceuticals
AG017: Precigen ActoBio
ZED1227: Falk Pharma and Zedira

Celiac Disease Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Celiac Disease.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Celiac Disease Epidemiology Segmentation:
The Celiac Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Celiac Disease Total Prevalence
Celiac Disease Prevalent Cases by severity
Celiac Disease Gender-specific Prevalence
Celiac Disease Diagnosed Cases of Episodic and Chronic

Celiac Disease Market Drivers:
Growing Awareness and Diagnosis Rates
Rising Demand for Gluten-Free Products
Advancements in Diagnostic Technologies
Increased Prevalence of Autoimmune Diseases

Celiac Disease Market Barriers:
Dietary Compliance Challenges
Misdiagnosis and Underdiagnosis
Regulatory Hurdles for New Treatments
Geographic Disparities in Access to Treatment

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Celiac Disease Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Celiac Disease Companies: 9 Meters Biopharma, ImmunogenX, Provention Bio, Takeda/Cour Pharmaceuticals, Precigen ActoBio, Falk Pharma, Zedira.
Key Celiac Disease Therapies: KAN-101, Larazotide Acetate (INN-202/AT-1001), Latiglutenase (IMGX003/ALV003), PRV-015, TAK-101, AG017, ZED1227.
Celiac Disease Therapeutic Assessment: Current marketed and emerging therapies
Celiac Disease Market Dynamics: Celiac Disease Market drivers and Celiac Disease barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Celiac Disease Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Celiac Disease market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Executive Summary of Celiac Disease (CD)
3. Competitive Intelligence Analysis for Celiac Disease (CD)
4. Celiac Disease (CD): Market Overview at a Glance
5. Celiac Disease (CD): Disease Background and Overview
6. Patient Journey
7. Celiac Disease (CD) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Celiac Disease (CD) Unmet Needs
10. Key Endpoints of Celiac Disease (CD) Treatment
11. Celiac Disease (CD) Marketed Products
12. Celiac Disease (CD) Emerging Therapies
13. Celiac Disease (CD): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Celiac Disease (CD)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.